REMTREX 2.5MG, 15MG,

Mechanism of Action:

• Capecitabine is converted enzymatically into 5-FU within tumor cells.

• 5-FU inhibits thymidylate synthase, preventing DNA replication and cell division.

• Selective activation in tumor tissue reduces systemic toxicity compared to direct 5-FU therapy.

Dosage & Administration:

• Typical dose: 1250 mg/m² orally twice daily for 14 days, followed by 7 days rest (21-day cycle).

• Dose adjustments are based on toxicity and patient condition.

• Tablets should be swallowed with water within 30 minutes after a meal.

(Only to be prescribed and supervised by an oncologist.)

Key Benefits:

• Oral chemotherapy – no hospitalization required.

• Tumor-targeted activation for better safety profile.

• Effective in multiple solid tumors including breast, colon, and gastric cancers.

Packaging:

• Box of 120 tablets (500 mg each)

• Also available in 150 mg strength (varies by brand/market)

Storage:

• Store below 25°C, in a dry place.

• Protect from light and moisture.

Important Notes:

• For oncology use only.

• Side effects may include hand-foot syndrome, diarrhea, nausea, fatigue.

• Dose modification required in renal impairment.

• Contraindicated in pregnancy and breastfeeding.